Clinical trials
Metastatic Adenocarcinoma clinical trials
Below are recruiting metastatic adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 245 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07466498RecruitingPhase 2
Estrogen patch for men with metastatic prostate cancer
This study tests whether an estrogen patch can improve quality of life for men with prostate cancer that has spread. It may be an option if you haven't started certain hormone treatments yet.
Seattle, WashingtonAges 18 years+ - NCT06056115Recruiting
Tislelizumab for lung cancer with brain metastases
This trial tests a drug called tislelizumab for people with advanced lung adenocarcinoma that has spread to the brain but is not causing symptoms. It is for those who have not had prior treatment and whose tumors do not have certain gene changes.
Shijiazhuang, HebeiAges 18–75 - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70 - NCT05821556RecruitingPhase 2
New drug combo test for untreated metastatic pancreatic cancer
This Phase 2 study tests a combination of medicines (including valproic acid and a statin) along with standard chemotherapy for people with newly diagnosed metastatic pancreatic cancer. The goal is to improve cancer control before any prior pancreatic cancer treatments and to see how well the medicines work and are tolerated.
Naples, ItalyAges 18 years+ - NCT04339218RecruitingPhase 3
Cryoablation plus pembrolizumab and chemotherapy for lung cancer spread
This trial studies whether freezing a small number of lung cancer spots (cryoablation) alongside standard immunotherapy (pembrolizumab) and chemotherapy can improve outcomes in people with metastatic lung adenocarcinoma. It’s meant for people who have measurable tumors that can be safely targeted with the freezing treatment.
Bordeaux, GirondeAges 18 years+ - NCT06616597RecruitingPhase 2
Targeting gut bacteria to help prostate cancer treatment work again
This trial tests whether adding metronidazole, an antibiotic, can make abiraterone work better in men with metastatic prostate cancer whose PSA is rising despite treatment. It aims to target gut bacteria that may be fueling resistance to the therapy.
Baltimore, MarylandAges 18 years+ - NCT06245356RecruitingPhase 2
A safety trial of trifluridine/tipiracil for DPD-deficient patients
This trial tests a chemotherapy drug (trifluridine/tipiracil) in people with metastatic colorectal or gastroesophageal cancer who have a DPD deficiency. DPD deficiency means your body may have trouble breaking down certain chemotherapy drugs, which can lead to serious side effects. This study aims to see if this drug is safe and effective for you.
AmiensAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Los Angeles, CaliforniaAges 18 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT03608631RecruitingPhase 1/Phase 2
Exosome treatment for KRAS-mutated metastatic pancreatic cancer
This Phase 1/2 study tests an investigational treatment made from “exosomes” for people with metastatic pancreatic cancer that has a specific KRAS mutation (KRAS G12D). It aims to see if this treatment can control the cancer and is safe for patients whose cancer has grown or stayed the same after prior chemotherapy.
Houston, TexasAges 18 years+ - NCT06649292RecruitingPhase 3
Study of SHR-A1904 for gastric cancer with CLDN18.2
This trial tests a new drug called SHR-A1904 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has already been treated once. It is for those whose tumors are positive for a protein called CLDN18.2.
Guangzhou, GuangdongAges 18–75 - NCT06696768RecruitingPhase 1
New drug plus standard chemotherapy for advanced colorectal cancer
This trial combines a new experimental drug (emavusertib) with standard chemotherapy (FOLFOX plus bevacizumab) for people with stage IV colorectal cancer who have not yet received chemotherapy. The goal is to see if the combination is safe and effective, potentially offering a new first-line treatment option.
Gainesville, FloridaAges 18 years+ - NCT07147231RecruitingPhase 1/Phase 2
Pidnarulex plus cemiplimab for MSS colorectal cancer
This trial tests two drugs together: pidnarulex (a targeted therapy) and cemiplimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced colorectal cancer that is microsatellite stable (MSS) and has not responded to current treatments, especially if their tumor has a MYC or FBXW7 change.
Aurora, ColoradoAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
RAS-targeting drugs for gastrointestinal cancers
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
Chandler, ArizonaAges 18 years+ - NCT07409272RecruitingPhase 3
Study of setidegrasib with chemo for pancreatic cancer
This trial tests a new drug called setidegrasib, given with two types of chemotherapy (mFOLFIRINOX or NALIRIFOX), for people whose pancreatic cancer has spread and has a specific genetic change called KRAS G12D. The goal is to see if adding setidegrasib helps control the cancer better than chemo alone.
Tucson, ArizonaAges 18 years+ - NCT06850545Recruiting
Lu-177 treatment for PSMA-positive metastatic prostate cancer
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
Kuopio, Northern SavoniaAges 18 years+ - NCT07130903RecruitingPhase 2
Fruquintinib plus special radio waves for advanced colon cancer
This trial tests whether combining fruquintinib (a pill) with low-level radio waves can help people whose metastatic colorectal cancer has stopped responding to or is intolerant of standard treatments. It’s for those who have tried certain chemotherapies and anti-VEGF therapy.
Bay City, MichiganAges 22 years+ - NCT06790602RecruitingPhase 2
Cemiplimab plus gemcitabine for metastatic pancreatic cancer
This trial tests a combination of an immunotherapy drug (cemiplimab) and chemotherapy (gemcitabine) for people with pancreatic cancer that has spread to other parts of the body. It is for those whose tumors have specific genetic changes (in the SWI/SNF genes) and have only had one prior treatment that was not immunotherapy.
La Jolla, CaliforniaAges 18 years+ - NCT06576115RecruitingPhase 2
Combination therapy with device for metastatic pancreatic cancer
This trial tests whether adding a non-invasive device that uses low-level radio waves to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with pancreatic cancer that has spread to other parts of the body.
Clarkston, MichiganAges 18 years+ - NCT06336902RecruitingPhase 1
Immunotherapy plus fasting diet and vitamin C for KRAS-mutated colorectal cancer
This trial tests a combination of two immunotherapy drugs (botensilimab and balstilimab) plus a fasting-mimicking diet and high-dose vitamin C for people with a specific type of advanced colorectal cancer (KRAS-mutated). It aims to see if this approach can help when standard treatments have stopped working.
Fullerton, CaliforniaAges 18 years+ - NCT05927857RecruitingPhase 1/Phase 2
Testing three medicines for advanced stomach cancer after first treatment
This study tests whether a combination of ramucirumab, nal-IRI (irinotecan liposome), and trifluridine/tipiracil can work better as a second treatment for metastatic stomach cancer. It may help people whose cancer has returned or progressed after only one prior treatment plan.
Taipei, Taiwan/TaipeiAges 20–80 - NCT01954992RecruitingPhase 3
Glufosfamide vs 5-FU for metastatic pancreatic cancer after gemcitabine
This study compares two chemotherapy drugs—glufosfamide and 5-FU—in people with pancreatic cancer that has spread and got worse after gemcitabine. It aims to see which option works better as a “second-line” treatment.
Whittier, CaliforniaAges 18 years+ - NCT05776524RecruitingPhase 2
Radiofrequency heat treatment for pancreas cancer spread to other organs
This Phase 2 trial tests whether a device that delivers carefully timed “radiofrequency heat” through the body can slow or control metastatic (spread) pancreatic cancer. You may qualify if you have newly diagnosed metastatic pancreatic cancer and can meet safety and blood-test requirements.
Winston-Salem, North CarolinaAges 18 years+ - NCT06698458Recruiting
DaRT radiation plus chemo for advanced pancreatic cancer
This trial tests a new type of radiation called DaRT (Alpha DaRT) combined with standard chemotherapy for people with pancreatic cancer that is locally advanced or has spread. The goal is to see if adding this radiation treatment can help shrink tumors or slow the cancer's growth.
Gilbert, ArizonaAges 18–120
Hear when a new Metastatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic adenocarcinoma?
- Yes. Clin2 currently lists 245 recruiting metastatic adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Metastatic Prostate Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Metastatic Gastric Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Metastatic Colorectal Adenocarcinoma
- Gastric Cancer Adenocarcinoma Metastatic
- Metastatic Esophageal Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.